Qian Ma

Qian Ma

Auto-generated profile, based on publicly available information

Qian Ma

Rare Brain Disorders Program, Department of Neurology The University of Texas Southwestern Medical Center Dallas Texas USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
JPJuan M. Pascual
Juan M. Pascual
PLPeiying Liu
Peiying Liu
DMDeng Mao
Deng Mao
DKDorothy I. Kelly
Dorothy I. Kelly
AHAna Hernandez
Ana Hernandez
HLHanzhang Lu
Hanzhang Lu
Glucose is the principal cerebral metabolic substrate under normal circumstances. Glucose provides energy (adenosine triphosphate) to neural cells and carbon for neurotransmitter production, one of the numerous biosynthetic reactions that the brain carries out, via glycolysis and the tricarboxylic acid (TCA) cycle.1 However, glucose metabolism also fulfills other, less-acknowledged cerebral biosynthetic requirements, which are no less important from a clinical standpoint when they remain unmet,2 such as anaplerosis (ie, the replenishment of intermediates that are normally lost from the TCA pool). Thus, a myriad of cerebral energetic and carbon fluxes, many of which are poorly understood quantitatively,3 stem from brain glucose availability. This is, in turn, contingent on the activity of the facilitative membrane glucose transporter type I (GLUT1), which permits glucose to cross the blood-brain barrier and subsequently transit into, and probably through, astrocytes.

17 October 2012 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
IMIsaac Marin-Valencia
Isaac Marin-Valencia
LGLevi B Good
Levi B Good
QMQian Ma
Qian Ma
CMCraig R Malloy
Craig R Malloy
JPJuan M Pascual
Juan M Pascual
It has been postulated that triheptanoin can ameliorate seizures by supplying the tricarboxylic acid cycle with both acetyl-CoA for energy production and propionyl-CoA to replenish cycle intermediates. These potential effects may also be important in other disorders associated with impaired glucose metabolism because glucose supplies, in addition to acetyl-CoA, pyruvate, which fulfills biosynthetic demands via carboxylation. In patients with glucose transporter type I deficiency (G1D), ketogenic diet fat (a source only of acetyl-CoA) reduces seizures, but other symptoms persist, providing the motivation for studying heptanoate metabolism. In this work, metabolism of infused [5,6,7-13C3]heptanoate was examined in the normal mouse brain and in G1D by13C-nuclear magnetic resonance spectroscopy, gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS). In both groups, plasma glucose was enriched in13C, confirming gluconeogenesis from heptanoate. Acetyl-CoA and glutamine levels became significantly higher in the brain of G1D mice relative to normal mice. In addition, brain glutamine concentration and13C enrichment were also greater when compared with glutamate in both animal groups, suggesting that heptanoate and/or C5 ketones are primarily metabolized by glia. These results enlighten the mechanism of heptanoate metabolism in the normal and glucosedeficient brain and encourage further studies to elucidate its potential antiepileptic effects in disorders of energy metabolism.

20 February 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
VJVikram Jakkamsetti
Vikram Jakkamsetti
IMIsaac Marin-Valencia
Isaac Marin-Valencia
QMQian Ma
Qian Ma
LGLevi B. Good
Levi B. Good
TTTyler Terrill
Tyler Terrill
JPJuan M. Pascual
Juan M. Pascual
Decreased metabolic flux due to deficient mitochondrial pyruvate dehydrogenase causes excitability dysfunction that can be modulated by acetate.

1 October 2012 in Neurobiology of Disease
Verified
Journal Article
Closed access
IMIsaac Marin-Valencia
Isaac Marin-Valencia
LGLevi B. Good
Levi B. Good
QMQian Ma
Qian Ma
JDJoao Duarte
Joao Duarte
TBTeodoro Bottiglieri
Teodoro Bottiglieri
JPJuan M. Pascual
Juan M. Pascual

1 November 2009 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
BPBelén Pérez-Dueñas
Belén Pérez-Dueñas
CPCatherina Prior
Catherina Prior
QMQian Ma
Qian Ma
EFEmilio Fernández-Álvarez
Emilio Fernández-Álvarez
XSXavier Setoain
Xavier Setoain
JPJuan M. Pascual
Juan M. Pascual
Objective To expand the spectrum of glucose transporter type 1 deficiency syndromes with a novel clinical and radiological phenotype not associated with microcephaly. Design Case report. Setting Two academic medical centers. Patient A 7-year-old patient followed up for 4 years. Results The patient exhibited a predominant syndrome of chorea and mental retardation associated with a combination of paroxysmal ataxia, dysarthria, dystonia and aggravated intellectual disability induced by fasting or exertion. She harbored a sporadic, heterozygous amino acid insertion in the GLUT1 transporter (insY292) that, in all likelihood, impaired blood-brain glucose flux. Her brain configuration appeared hypotrophic via magnetic resonance imaging, particularly over the occipital lobes. A ketogenic diet resulted in brain growth that accompanied a favorable symptomatic outcome. Conclusions To date, glucose transporter type 1 deficiency syndrome includes several epileptic and movement disorder phenotypes caused by the clinical expressivity of the prominent cortical, basal ganglia, and cerebellar abnormalities found in the disease, but hypomorphic or novel variants are probably yet to be discovered.

5 October 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
KRKarthik Rajasekaran
Karthik Rajasekaran
QMQian Ma
Qian Ma
LGLevi B. Good
Levi B. Good
GKGauri Kathote
Gauri Kathote
VJVikram Jakkamsetti
Vikram Jakkamsetti
JPJuan M. Pascual
Juan M. Pascual
Individuals with glucose transporter type I deficiency (G1D) habitually experience nutrient-responsive epilepsy associated with decreased brain glucose. However, the mechanistic association between blood glucose concentration and brain excitability in the context of G1D remains to be elucidated. Electroencephalography (EEG) in G1D individuals revealed nutrition time-dependent seizure oscillations often associated with preserved volition despite electrographic generalization and uniform average oscillation duration and periodicity, suggesting increased facilitation of an underlying neural loop circuit. Nonlinear EEG ictal source localization analysis and simultaneous EEG/functional magnetic resonance imaging converged on the thalamus-sensorimotor cortex as one potential circuit, and 18 F-deoxyglucose positron emission tomography ( 18 F-DG-PET) illustrated decreased glucose accumulation in this circuit. This pattern, reflected in a decreased thalamic to striatal 18 F signal ratio, can aid with the PET imaging diagnosis of the disorder, whereas the absence of noticeable ictal behavioral changes challenges the postulated requirement for normal thalamocortical activity during consciousness. In G1D mice, 18 F-DG-PET and mass spectrometry also revealed decreased brain glucose and glycogen, but preserved tricarboxylic acid cycle intermediates, indicating no overall energy metabolism failure. In brain slices from these animals, synaptic inhibition of cortical pyramidal neurons and thalamic relay neurons was decreased, and neuronal disinhibition was mitigated by metabolic sources of carbon; tonic-clonic seizures were also suppressed by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor inhibition. These results pose G1D as a thalamocortical synaptic disinhibition disease associated with increased glucose-dependent neuronal excitability, possibly in relation to reduced glycogen. Together with findings in other metabolic defects, inhibitory neuron dysfunction is emerging as a modulable mechanism of hyperexcitability.